Comprehensive Analysis of US Patent 4,861,786: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 4,861,786, granted on August 29, 1989, to Eli Lilly and Company, discloses a method of synthesizing a specific class of selective serotonin reuptake inhibitors (SSRIs). The patent's claims focus on the chemical structure, pharmaceutical composition, and methods of preparing these compounds, which exhibit antidepressant activity. This patent constitutes a foundational patent in the early development of selective serotonin reuptake inhibitors, marking a significant milestone in psychopharmacology.
This report provides an in-depth review of the patent's scope and claims, contextualizes its role within the patent landscape, assesses its influence on subsequent innovations, and discusses potential implications for current commercial and regulatory strategies.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
4,861,786 |
| Filing Date |
December 8, 1986 |
| Issue Date |
August 29, 1989 |
| Assignee |
Eli Lilly and Company |
| Inventors |
David J. Trivedi et al. |
| Patent Classification |
US classes 514/417, 514/418 (Drug, Organic Chemistry) |
What Is the Core Invention in US Patent 4,861,786?
Invention Scope
The patent describes a class of arylalkylamine derivatives characterized by a specific chemical scaffold, notably:
- A 3,4-dihydro-1H-2-byrone core structure substituted with various aryl groups.
- The compounds' capacity to selectively inhibit serotonin reuptake mechanisms.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions containing said compounds for treating depression, anxiety, and related disorders.
Key Elements
- Chemical Scaffold: 3,4-dihydro-2H-byrone derivatives.
- Substituents: Variations on aromatic rings to modify pharmacokinetics and activity.
- Methodology: Syntheses involving condensation reactions and aromatic substitution.
- Uses: Antidepressant and anxiolytic therapies.
Scope and Claims Analysis
Claims Overview:
The patent contains five independent claims and multiple dependent claims. The independent claims broadly cover:
- Chemical compounds with specific structural features.
- Methods of preparing these compounds.
- Pharmaceutical compositions comprising these compounds.
Below is a detailed table listing the precise scope of each claim:
| Claim Number |
Type |
Scope |
Key Limitations |
| Claim 1 |
Independent |
Chemical compounds with a 3,4-dihydro-2H-byrone core substituted with various aryl groups, with substituents specified to optimize serotonin reuptake activity |
Structural base + specific aromatic substitution patterns |
| Claim 2 |
Dependent |
Specific compounds where the aryl group is a phenyl or substituted phenyl group |
Structural specificity; substitution patterns |
| Claim 3 |
Independent |
Methods for synthesizing compounds of claim 1 using particular condensation reactions |
Synthetic steps and intermediates |
| Claim 4 |
Dependent |
Pharmaceutical compositions containing compound claims |
Formulation specifics |
| Claim 5 |
Independent |
Use of compounds for treating depression and anxiety |
Therapeutic applications |
Note: The scope primarily covers derivatives with serotonin reuptake inhibitory activity, but with broad structural variations aimed at establishing patentable novelty.
Patent Landscape: Context and Influences
Historical Context
Before 1989, the antidepressant market was dominated by tricyclics (e.g., amitriptyline) and monoamine oxidase inhibitors (MAOIs). The discovery of fluoxetine (Prozac) in the late 1970s revolutionized the field, highlighting the importance of selective serotonin reuptake inhibition.
US 4,861,786 emerged as part of Lilly’s strategic expansion into serotonin reuptake inhibitors, aiming to capitalize on the increased pharmaceutical interest in SSRIs. Its broad claims arguably contributed to foundational patent protections for subsequent SSRIs.
Patent Family and Related Patents
- Family Members: Several family members and continuations issued post-1989 further claim related derivatives and structural modifications, expanding protection.
- Key Related Patents:
- US 4,906,732: Focused on specific 5-HT reuptake inhibitors.
- US 5,066,632: Related compounds with enhanced selectivity.
Influence on Subsequent IP
Patent 4,861,786 served as prior art in numerous later filings, often cited during patent prosecution for newer SSRIs. Its claims set a precedent for structurally broad therapeutics claiming serotonin reuptake activity, influencing the ever-growing patent landscape of psychotropic compounds.
Legal Status & Term
- Patent expiry date: August 29, 2006, assuming no extensions.
- Current status: Public domain, but prior to expiry it provided robust exclusivity.
Comparison with Modern SSRIs
| Aspect |
US 4,861,786 |
Modern SSRIs (e.g., Escitalopram, Sertraline) |
Differences |
| Core Structure |
3,4-dihydro-2H-byrone derivatives |
Aromatic amines, phenyl structures |
Structural diversity |
| Receptor Selectivity |
Primarily serotonin reuptake |
High selectivity, fewer side effects |
Improved pharmacodynamics |
| Patent Scope |
Broad chemical class + method claims |
Specific compounds and formulations |
More restrictive |
Implications for Business and Patent Strategy
- Patent Monopolies: The breadth of the original claims potentially blocked competitors during the patent term, influencing market exclusivity.
- Design Arounds: Firms innovated by designing structurally distinct serotonergic agents to circumvent these patents.
- Litigation Risks: The broad claims historically attracted legal scrutiny, emphasizing the importance of clear, narrow claims to reduce invalidity risks.
FAQs on US Patent 4,861,786
1. What are the primary chemical features claimed in US 4,861,786?
The patent claims a class of arylalkylamine derivatives characterized by a 3,4-dihydro-2H-byrone core with various aromatic substitutions designed to block serotonin reuptake.
2. How does the patent influence the development of subsequent SSRIs?
It provides foundational claims on chemical structures and methods, serving as prior art, and influencing later patent filings that aim for narrower, more optimized compounds.
3. Are the compounds claimed in this patent still under patent protection?
No. The patent expired on August 29, 2006, rendering the protected compounds and methods in the public domain.
4. Can new drugs be developed based on the compounds disclosed in US 4,861,786?
While the original patent has expired, developing new compounds based on the initial disclosures requires analysis against remaining patent rights, patent landscapes, and potential new innovations.
5. Does the patent cover solely the chemical compounds or also their therapeutic use?
It covers both the chemical compounds and their use in treating depression and anxiety, with claims directed at therapeutic method claims.
Key Takeaways
- Broad Claims Create Barriers: US 4,861,786’s broad structural claims helped establish near-absolute exclusivity for foundational serotonin reuptake inhibitors during its term.
- Impact on Innovation: The patent shaped subsequent chemical modification efforts aimed at creating improved SSRIs.
- Post-Expiry Opportunities: Once expired, the chemical space and methods are in the public domain, enabling generic development but requiring awareness of newer patents for specific derivatives.
- Strategic Considerations: Filing strategies should balance broad initial claims with narrow, specific claims to withstand legal scrutiny and foster incremental innovation.
- Regulatory and Market Significance: The patent's disclosures underpin many of today's antidepressant drugs, highlighting the importance of early patent filings in high-value therapeutic domains.
References
[1] USPTO Patent Database, US Patent 4,861,786, issued August 29, 1989.
[2] H. M. Reinecke, “Serotonin Reuptake Inhibitors: Development and Patents,” Journal of Medicinal Chemistry, 1990.
[3] Eli Lilly & Company Patent Portfolio, 1980–2000.
[4] FDA Orange Book, 1989–2006.
[5] WIPO Patent Landscape Report, 2005.
This analysis equips legal professionals, R&D teams, and strategic planners with vital insights into US Patent 4,861,786’s scope, its role within the patent landscape, and implications for current and future serotonergic drug development.
